logo
Kindergarten is the cut off for children waiting for public speech-language therapy

Kindergarten is the cut off for children waiting for public speech-language therapy

Yahoo24-06-2025
The clock is ticking for parents of young children requiring speech-language therapy in Newfoundland and Labrador.
Seventy speech-language pathologists (SLP) are handling cases on a full-time basis, with an additional seven SLPs working casually for Newfoundland and Labrador Health Services in eastern Newfoundland.
Eleven of those work in child development — the unit where most children on the province's waitlist for speech-language assessments and treatment sit.
Kelsey Oake, who lives in Triton, N.L., says her three-year-old son, Rhett, has been waiting for speech-language therapy and an autism assessment since he was 18 months old.
"We started noticing that he had traits of autism," Oake said. "We kind of tried to be proactive."
Now, she said, Rhett is three, and in the fall of 2027 he will start kindergarten.
That means Oake has 26 months for her son to be diagnosed and receive treatment before he will age out of the public health-care system's waitlist for speech-language therapy.
Oake already waited up to 14 months for an initial speech-language evaluation, she said.
Now her son has to wait up to 20 months for treatment and up to 31 months for an autism assessment.
If Rhett starts school without any treatment, Oake expects her son to struggle.
"From what I've gathered, from other people who have similar situations, is that without a proper diagnosis he won't have support aids in school," Oake said. "My son has a form of aggression issues. Like if he ends up doing that towards other children, there won't be like an IRT or student support there with him."
Oake said her only option to guarantee her son additional support is to go through the private system for treatment and a diagnosis, but she doesn't have insurance and can't afford it out of pocket.
"It's a very hefty bill. I know some places offer payment plans, which is wonderful for people who are in my situation. But, like, I don't feel that a mother or anybody who's in my situation should have to literally bring themselves to the brink of bankruptcy just to get their child seen," she said.
Amelia Hickey knows the struggle of paying for private care. Her four-year-old daughter has autism. She receives speech-language therapy privately — a decision Hickey made to ensure her daughter gets treatment before starting kindergarten in 2026.
"We are fortunate we have health insurance. However, it's June, and our health insurance maxed out last month, which means that we are now spending the money directly out of pocket," Hickey said.
Her daughter is on the waitlist for speech-language therapy through NLHS. She received a speech-language assessment during what Hickey said was called "an assessment blitz."
"They basically just assessed everybody who had been on the waitlist at that point," Hickey told CBC News. "After you do that, it's 18 to 24 months. So she'll never actually see [a] Janeway speech language pathologist, essentially."
With her diagnosis, Hickey's daughter will see an SLP in school, but it won't replace her private care because of their caseload numbers.
"My daughter will have to miss school, and then I'll have to miss work to be able to continue to take her to these appointments when it should be available to her through the system," Hickey said.
In the provincial legislature last month, Health Minister Krista Lynn Howell said, "Once a teacher or support person identifies that a child has a particular need, then supports can be put in place immediately."
Hickey said that's not the case.
"There are situations I know of where parents send their kid to school, and they're only allowed to go to school an hour a day," she said. "How do you, as a parent, maintain a job and do all the other things if you have other children, if one of your children can only go to school for an hour a day?"
CBC News has requested interviews with the Department of Health and the Department of Education.
Download our to sign up for push alerts for CBC Newfoundland and Labrador. Sign up for our . Click .
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

Yahoo

time4 hours ago

  • Yahoo

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

The global cell dissociation market is valued at USD 461.55 million in 2025 and is projected to reach approximately USD 1,451.89 million by 2034, expanding at a CAGR of 13.58% during the forecast period. Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global cell dissociation market size valued at USD 406.36 million in 2024, is projected to reach approximately USD 1,451.89 million by 2034, growing at a CAGR of 13.58%, according to a study by , a sister company of Precedence Research. Widespread application of cell dissociation in diagnostics, study of diseases, isolation of various cell products, etc, due to which the cell dissociation market is progressing. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America led the market share by 38% in 2024. Asia Pacific is expected to be the fastest-growing region in the coming years. By product, the enzymatic dissociation segment dominated the cell dissociation market in 2024. By product, the non-enzymatic dissociation segment is expected to grow at the fastest CAGR during 2025-2034. By type, the tissue dissociation segment held a major share of the market in 2024. By type, the cell detachment segment is expected to witness rapid expansion in the studied years. By end-user, the pharmaceutical & biotechnology companies segment led the cell dissociation market in 2024 and is expected to grow rapidly during the forecast period. Market Overview & Potential The process in which individual cells are separated from a tissue or cell culture, usually for research or therapeutic applications, is known as cell dissociation. Primarily, they are employed in stem cell research, cancer research, tissue engineering, and drug discovery. Currently, the cell dissociation market is experiencing progression in enzymatic and mechanical methods, as well as the involvement of innovative technologies, such as portable electrical devices. Basic use of cell dissociation in the development of regenerative medicine encompasses cell isolation, manipulation, and then reintroduction into the body. Market Scope Metric Details Market Size in 2024 USD 406.36 Million Projected Market Size in 2034 USD 1451.89 Million CAGR (2025 - 2034) 13.58 % Leading Region North America Market Segmentation By Product, By Type, By End-use, By Region Top Key Players Merck KGaA, Thermo Fisher Scientific, Danaher Corp., STEMCELL Technologies, Sartorius AG, BD, Miltenyi Biotec, PAN-Biotech, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., S2 Genomics, Inc. What are the Key Growth Drivers Involved in The Expansion of The Market? Around the world, the developing utilization of cell-based assays in drug discovery and development, as well as in customized medicine, is leading to an increased demand for robust cell dissociation products. The cell dissociation market is further driven by tremendous applications in the escalating demand for cell-based therapies, especially stem cell and gene therapies. Besides this, advancing research techniques, like automation and integration with omics technologies, are supporting process efficiency and further expansion of the market. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Trends Associated with the Cell Dissociation Market? In 2025, the growing emergence of numerous biotechnology and pharmaceutical industries in research and development is impacting the overall market growth. In July 2025, SPT Labtech, a global company in innovative laboratory automation, collaborated with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, to advance automated cell-based assay workflows. In April 2025, EditCo Bio, Inc. and Promega Corporation partnered to empower the era of biologically related cell-based research, such as HiBiT, HaloTag®, and NanoLuc® technologies. In November 2024, Singleron Biotechnologies, a player in single-cell analysis solutions, made a partnership with TOMY Digital Biology Co., Ltd to enable access to Singleron's comprehensive range of single-cell analysis products and services. What Is the Major Limitation in the Market? The cell dissociation market is facing certain challenges, mainly the maintenance of high cell viability and purity after the dissociation process in the production of biopharmaceuticals and cell-based therapies. Besides this, expensive specialized enzymes, automated systems, and other reagents are creating a hindrance to developing cell dissociation technologies. Regional Analysis Become a valued research partner with us - Why did North America Dominate the Cell Dissociation Market in 2024? The market is propelled by immense investments in life sciences research in this region, impacting market development, primarily in the US. Moreover, this region possesses advanced biotechnology and a pharmaceutical industry, and a strong healthcare infrastructure. Along with this, North America's emphasis on the development of precision medicine, 3D cell culture models, and advanced therapies like gene editing is expanding demand for more sophisticated and effective cell dissociation solutions. For instance, In March 2025, RoslinCT and Ayrmid Pharma made a strategic partnership for the production of Omisirge®, a treatment for hematologic malignancies commercialized in the United States by Gamida Cell, a subsidiary of Ayrmid Pharma. In October 2024, FibroBiologics Inc., a clinical-stage biotechnology company, and Charles River Laboratories, a leading drug discovery, development, testing, and manufacturing solutions provider, signed an agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628. What Made the Asia Pacific Significantly Grow in the Market in 2024? During 2025-2034, the Asia Pacific will expand at the fastest CAGR in the cell dissociation market. Combined factors are impacting the overall market expansion in the ASAP countries, such as China. Japan, India, and South Korea. An expanding healthcare system, with increased focus on R&D, especially in regenerative medicine and stem cell research, is widely involved in the market expansion. Apart from this, ongoing government initiatives to boost the biotechnology domain and accelerate the pipeline in clinical research activities are also propelling the adoption of innovative technologies. For this market, In August 2025, CytoNiche Biotech, a leader in 3D cell production technology, inaugurated its 3D FloTrix™ Experience Hub in Singapore. In July 2025, NKGen Biotech, Inc., a clinical-stage biotechnology company, and Japan-based HekaBio K.K., partnered to expand the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By product analysis How did the Enzymatic Dissociation Segment Lead the Market in 2024? In 2024, the enzymatic dissociation segment registered dominance in the cell dissociation market. This type of product can give higher cell yield with broader effectiveness at extracting cells from dense or complex tissues as compared to other mechanical methods. Moreover, this approach offers its flexibility in different downstream applications, like flow cytometry, cell sorting, and in vitro assays. Alongside its wide-range utilization in the development of numerous cell-based therapies and its ability to minimize the amount of fibrous connective tissue present in the cell suspension, it boosts further cell viability and downstream analysis in the market. However, the non-enzymatic dissociation segment is predicted to experience rapid growth in the studied years. This product type has several advantages, like it can preserve cell surface proteins, which is vital for downstream assays. Furthermore, non-enzymatic dissociation is favourable for sensitive cells. Also, they are obtained without animal-derived components, making them adaptable for various cell-based therapies is driving overall segment and market expansion. Whereas, non-enzymatic dissociation is greatly employed in isolating and expanding MSCs while protecting their key functional properties. By type analysis Which Type Held the Largest Share of the Cell Dissociation Market in 2024? The tissue dissociation segment dominated the market with a major share in 2024. The segment is driven by rising research in oncology, chronic conditions, and breakthroughs in cell-based therapies. This type mainly contributes to the separation of cells from a tissue sample to create a single-cell suspension, which is further necessary for isolating cells for therapeutic use, research, and diagnostics. Moreover, the cell detachment segment is estimated to grow fastest during 2025-2034. The significance of cell detachments in cell culture, particularly in culturing adherent cells, is increasingly applied in many research and therapeutic applications. Along with this, a rise in demand for monoclonal antibodies in biopharmaceutical and pharmaceutical industries is immensely dependent on cell culture and, consequently, cell detachment techniques. Eventually, they encompass mechanical detachment (scraping or shaking) and physical methods, such as thermal, light, or magnetic manipulation, which can be selected based on the cell type, culture conditions, and downstream applications. By end-user analysis What Made the Pharmaceutical & Biotechnology Companies Segment Dominate in the Market in 2024? The pharmaceutical & biotechnology companies segment was dominant in the cell dissociation market in 2024 and will expand at the fastest CAGR. Widespread use of cell dissociation is seen in these companies, particularly in vaccine development, production of diverse biopharmaceutical products, and cancer research. Additionally, the segment is fueled by the adoption of cell dissociation in drug discovery and development, allowing the generation of single-cell suspensions, which are essential for high-throughput screening of possible drug candidates. The utilization of the single-cell RNA sequencing (scRNA-seq) technique relies on cell dissociation for the analysis of gene expression profiles in individual cells, demonstrating significant insights into drug responses and cellular heterogeneity. Recent Developments in the Cell Dissociation Market In July 2025, AscellaHealth, a leading partner delivering customizable solutions to support the specialty pharmaceutical industry, partnered with Abeona Therapeutics Inc. for pre- and post-launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy. In April 2025, Singleron Biotechnologies launched PythoN i, an advanced tissue having in nuclei extraction and tissue homogenization functions to its tissue processing system. In March 2025, Sphere Bio, a major provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, introduced the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the Company's new Cyto-Mine® Chroma platform. In April 2024, Kuraray Co., Ltd. developed PVA (Polyvinyl Alcohol) hydrogel microcarriers for cell cultures used in regenerative medicine. Browse More Insights of Towards Healthcare: The global single-cell sequencing market was valued at US$ 1.63 billion in 2024 and is anticipated to rise to US$ 1.88 billion by 2025. By 2034, the market is projected to exceed US$ 6.65 billion, advancing at a CAGR of 15.05%. The global cellular immunotherapy market reached US$ 11.33 billion in 2024 and is expected to grow to US$ 13.87 billion in 2025, before surging to nearly US$ 85.78 billion by 2034, expanding at a robust CAGR of 22.45% during the forecast period. The global cell and gene therapy clinical trials market was valued at US$ 10.8 billion in 2024, grew to US$ 12.47 billion in 2025, and is projected to achieve US$ 45.31 billion by 2034, registering a CAGR of 15.43% from 2025 to 2034. The global cell-based assays market stood at US$ 17.29 billion in 2024 and is forecast to increase to US$ 18.82 billion in 2025. By 2034, it is anticipated to surpass US$ 39.92 billion, advancing at a CAGR of 8.84%. The global biopharmaceutical contract manufacturing market was calculated at US$ 40.14 billion in 2024, expanded to US$ 44.61 billion in 2025, and is projected to reach approximately US$ 115.65 billion by 2034, growing at a CAGR of 11.14% between 2025 and 2034. The global cell and gene solutions market is on a strong growth trajectory, with revenue expected to scale significantly over the forecast years from 2025 to 2034, potentially reaching into the hundreds of millions. The global cell-based immunotherapies market was valued at US$ 4.59 billion in 2024, is set to grow to US$ 5.28 billion in 2025, and is projected to generate US$ 18.62 billion by 2034, expanding at a CAGR of 15.02% throughout the forecast period. The global cell banking outsourcing market reached US$ 14.37 billion in 2024, expanded to US$ 16.72 billion in 2025, and is forecast to hit US$ 63.49 billion by 2034, growing at a strong CAGR of 16.37%. The global stem cell banking market was valued at US$ 7.85 billion in 2024, grew to US$ 9.12 billion in 2025, and is projected to climb to US$ 35.12 billion by 2034, advancing at a CAGR of 16.14% between 2025 and 2034. The global host cell protein testing market stood at US$ 2.37 billion in 2024, increased to US$ 2.56 billion in 2025, and is projected to cross US$ 5.19 billion by 2034, expanding at a CAGR of 8.17%. The global stem cell assay market was valued at US$ 2.68 billion in 2024, grew to US$ 3.15 billion in 2025, and is expected to achieve US$ 13.5 billion by 2034, rising at a significant CAGR of 17.55%. The global live cell imaging market reached US$ 2.92 billion in 2024, expanded to US$ 3.16 billion in 2025, and is anticipated to generate US$ 6.49 billion by 2034, progressing at a CAGR of 8.34%. The global immortalized cell line market was valued at US$ 4.55 billion in 2024, increased to US$ 4.85 billion in 2025, and is projected to attain US$ 8.68 billion by 2034, advancing at a CAGR of 6.71%. The global cell viability assays market stood at US$ 1.89 billion in 2024, grew to US$ 2.05 billion in 2025, and is projected to reach US$ 4.24 billion by 2034, expanding at a CAGR of 8.54%. The global stem cell reconstructive market was valued at US$ 1.56 billion in 2024, is forecast to grow to US$ 1.88 billion in 2025, and is expected to achieve US$ 10.32 billion by 2034, advancing at an impressive CAGR of 20.81%. Cell Dissociation Market Key Players Merck KGaA Thermo Fisher Scientific Danaher Corp. STEMCELL Technologies Sartorius AG BD Miltenyi Biotec PAN-Biotech HiMedia Laboratories F. Hoffmann-La Roche Ltd. S2 Genomics, Inc. Segments Covered in The Report By Product Enzymatic Dissociation Trypsin Collagenase Elastase Papain Hyaluronidase DNase Others Non-enzymatic dissociation Instruments & Accessories By Type Tissue Dissociation Cell Detachment By End-use Pharmaceutical & Biotechnology Companies Research & Academic Institutes By Region North America U.S. Canada Mexico Europe Germany UK Spain Italy France Denmark Norway Sweden Asia Pacific Japan China India Australia Thailand South Korea Latin America Brazil Argentina MEA South Africa Saudi Arabia UAE Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Behavioral Activation Therapy Cuts Perinatal Suicide Risk
Behavioral Activation Therapy Cuts Perinatal Suicide Risk

Medscape

time4 hours ago

  • Medscape

Behavioral Activation Therapy Cuts Perinatal Suicide Risk

TOPLINE: In a study of 1117 perinatal adults receiving behavioral activation therapy, the odds of endorsing suicide ideation decreased by 25% with each treatment session and by 80% at 3 months post-randomization, with specialist and nonspecialist providers showing equal effectiveness. METHODOLOGY: A multisite, noninferiority, four-arm randomized clinical trial called the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) compared clinicians (nonspecialist vs specialist) and modalities (telemedicine vs in-person) in delivering behavioral activation therapy. Research was conducted at university-affiliated networks in Chicago, Illinois; Chapel Hill, North Carolina; and Toronto, Ontario, Canada. Participants included pregnant (≤ 36 weeks) and postpartum (4-30 weeks) adults with depressive symptoms (Edinburgh Postnatal Depression Scale score ≥ 10). A total of 1117 participants who completed at least one treatment session and provided ≥ 1 week of Edinburgh Postnatal Depression Scale data were included in the analysis. Treatment consisted of a manualized 6- to 8-session perinatal behavioral activation intervention delivered weekly. TAKEAWAY: Among 1230 enrolled pregnant and postpartum adults, 1117 completed at least one treatment session, with 264 (23.6%) endorsing suicide ideation during treatment. The odds of endorsing suicide ideation decreased by 25% with each additional treatment session (odds ratio [OR], 0.75; 95% CI, 0.58-0.96; P = .03). At 3 months post-randomization, the odds of endorsing suicide ideation decreased by 80% compared with any time during treatment (OR, 0.20; 95% CI, 0.14-0.27; P < .001). No significant differences were found in the odds of endorsing suicide ideation between clinician types (nonspecialist vs specialist) or delivery modalities (telemedicine vs in person). IN PRACTICE: 'Behavioral activation is a first-line recommended treatment for perinatal depression and may reduce postpartum suicide risk by increasing values-consistent living and awareness of ineffective behaviors,' wrote the authors of the study. SOURCE: The study was led by Parisa Kaliush, PhD, Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, and Daisy Singla, PhD, Centre for Addiction and Mental Health in Toronto. It was published online in JAMA Psychiatry. LIMITATIONS: High suicide risk prompted exclusion from SUMMIT trial, and the final sample was highly educated, suggesting some limitations in generalizability. However, the prevalence of suicide ideation at baseline (15.0%) was higher than previously cited rates. DISCLOSURES: This study was funded by the Patient-Centered Outcomes Research Institute. Bradley Gaynes, PhD, disclosed receiving compensation for authorship/review of UpToDate chapters on depression. Samantha Meltzer-Brody, MD, MPH, reported receiving research funding to the University of North Carolina for clinical trials sponsored by Sage Therapeutics, Electromedical Products International, and Sirtsei Pharmaceuticals, serving as a clinical advisor and professional corporation owner for Modern Health, and serving as a scientific advisor to EmbarkNeuro and Seaport Therapeutics. Simone Vigod, MD, disclosed receiving royalties from UpToDate for authorship of materials on depression and pregnancy. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store